Page 3 - டிஜிட்டல் சிகிச்சை கூட்டணி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

VOLUNTIS: Voluntis, a pioneer-turned-leader in digital therapeutics, sets out its ambitions for profitable growth

VOLUNTIS: Voluntis, a pioneer-turned-leader in digital therapeutics, sets out its ambitions for profitable growth Cambridge (USA), Paris (France), May 5, 2021, 5:45 p.m. CET - Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960), a leader in the field of digital therapeutics, today presents a review of its recent years development and reveal its ambitions for the coming years. Pierre Leurent, CEO of Voluntis, said: It has been just over 10 years since we signed our first biopharma licensing agreement providing a pharmaceutical company access to our technological solutions. This decade has allowed us to build a solid foundation for a replicable and value-creating global business model. Just one year ago, we announced our intention to accelerate the commercial momentum on these fundamentals and the inflection is now clear, both in terms of the number of licensing agreements signed and the average size of the partnerships. Our agreement announced a few days ago with

United kingdomFrance generalVivien ferranGuillaume flochPierre leurentVoluntis groupBristol myers squibbDigital therapeutics allianceUnited statesEuronext growth parisDigital therapeuticsPerformance indicatorsFinancial reportஒன்றுபட்டது கிஂக்டம்பிரான்ஸ் ஜநரல்விவியென் ஃபெரான்

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF - Webinar will be held today at 15:00 CET (9:00 am EST) - Digital therapeutics expert Jessica Shull joins Vicore to drive DTx program News provided by Share this article GOTHENBURG, Sweden, May 4, 2021 /PRNewswire/ Vicore Pharma Holding AB (publ) ( Vicore ), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces the signing of an agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx Platform . Vicore will hold a webinar at 15:00 CET (9 AM EST) today to outline the strategic importance and operational details of the new program.

Vastra gotalands lanVicore pharmaJohn drakenberg renanderCarl johan dalsgaardVicore pharma holdingDigital therapeutics allianceAlex therapeuticsJessica shullDigital therapeuticsAlex therapeuticJohan dalsgaardDrakenberg renanderNasdaq stockholmNicotine addictionPharma holdingVicore pharma holding ab

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Vastra gotalands lanVicore pharmaJohn drakenberg renanderCarl johan dalsgaardVicore pharma holdingDigital therapeutics allianceAlex therapeuticsJessica shullDigital therapeuticsAlex therapeuticJohan dalsgaardDrakenberg renanderNasdaq stockholmNicotine addictionPharma holdingடிஜிட்டல் சிகிச்சை கூட்டணி

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Vastra gotalands lanVicore pharmaJohn drakenberg renanderCarl johan dalsgaardVicore pharma holding ab carl johan dalsgaardVicore pharma holdingDigital therapeutics allianceAlex therapeuticsJessica shullDigital therapeuticsAlex therapeuticJohan dalsgaardDrakenberg renanderNasdaq stockholmNicotine addictionPharma holding

Kaia Health Raises $75M in Series C Funding

Kaia Health, a NYC-based digital therapeutics company, raised a $75m Series C funding round. The round was led by an unnamed growth equity fund with participation from existing investors Optum Ventures, Eurazeo, capital300, Balderton Capital, Heartcore Capital, Symphony Ventures (the investment vehicle of golf legend Rory McIlroy) and A Round Capital. The company, which has raised a total of $125m to date, intends to use the funds to grow its commercial team, accelerate product and partnership development and extend the offering within Europe. Led by CEO, President, and Founder Konstantin Mehl, Kaia Health is a digital therapeutics company that creates evidence-based treatments for a range of disorders including back pain, COPD and osteoarthritis. Working with experts across medical fields, the company uses machine learning to deliver individualized app interventions that aim to empower and motivate patients to take control and self-manage their condition with digital alternativ

Konstantin mehlRory mcilroyKaia healthDigital therapeutics allianceOptum venturesBalderton capitalHeartcore capitalSymphony venturesFounder konstantin mehlராரீ அம்கில்‌ராய்கைய ஆரோக்கியம்டிஜிட்டல் சிகிச்சை கூட்டணிஆப்டம் முயற்சிகள்ஹார்ட்கோர் மூலதனம்சிம்பொனி முயற்சிகள்